Supplementary Table 1 SULFO-TAG labeled and biotinylated belimumab solution concentrations used in the ECL assay Company SULFO-TAG labeled Biotinylated belimumab belimumab (μg/mL) (μg/mL) A 0.25 0.75 B 0.5 0.5 C 2.0 1.0 D 0.25 1.0 E 0.5 0.5 F 0.125 0.125 G 0.2 1.0 H 2.0 1.0 J 1.0 1.0 Supplementary Table 2 Experimental condition for determination of minimum required dilution (MRD) Company Dilution (fold) ADA (ng/mL) n run A 2, 5, 10, 50, 2.5, 5, 10, 20, 40, 80, 160, 320, 2 1 100 640, 1,280, 2,560 C 3, 10, 30, 50, 5, 25, 125, 625, 3,125, 15,625, 2 1 100 78,125 D 1, 4, 10, 100 7.41, 20.8, 58.1, 163, 456, 2 1 1,276, 3,571, 10,000 F 1, 2, 5, 10, 0.46, 1.4, 4.1, 12, 37, 111, 333 2 1 100 G 100, 1000, 0.97, 1.95, 3.91, 7.81, 15.6, 2 1 10000 31.3, 63, 500, 1,000 H 1, 2, 10 20, 200, 2,000 2 1 I 1, 2, 10 31.3, 62.5, 125, 250, 500, 2 1 1,000, 2,000 Supplementary Table 3 Experimental conditions for calculation of screening assay precision Company ADA (ng/mL) n Runs A 20, 1000 3 6 B 200, 1,250, 4,000 6 (1 run), 4 (2 runs) 3
Supplementary Table 1 SULFO-TAG labeled and biotinylated belimumab solution concentrations used in the ECL assay Company SULFO-TAG labeled belimumab (μg/mL) Biotinylated belimumab (μg/mL) A 0.25 0.75 B 0.5 0.5 C 2.0 1.0 D 0.25 1.0 E 0.5 0.5 F 0.125 0.125 G 0.2 1.0 H 2.0 1.0 J 1.0 1.0 Supplementary Table 2 Experimental condition for determination of minimum required dilution (MRD) Company Dilution (fold) ADA (ng/mL) n run A 2, 5, 10, 50, 100 2.5, 5, 10, 20, 40, 80, 160, 320, 640, 1,280, 2,560 2 1 C 3, 10, 30, 50, 100 5, 25, 125, 625, 3,125, 15,625, 78,125 2 1 D 1, 4, 10, 100 7.41, 20.8, 58.1, 163, 456, 1,276, 3,571, 10,000 2 1 F 1, 2, 5, 10, 100 0.46, 1.4, 4.1, 12, 37, 111, 333 2 1 G 100, 1000, 10000 0.97, 1.95, 3.91, 7.81, 15.6, 31.3, 63, 500, 1,000 2 1 H 1, 2, 10 20, 200, 2,000 2 1 I 1, 2, 10 31.3, 62.5, 125, 250, 500, 1,000, 2,000 2 1 Supplementary Table 3 Experimental conditions for calculation of screening assay precision Company ADA (ng/mL) n Runs A 20, 1000 3 6 B 200, 1,250, 4,000 6 (1 run), 4 (2 runs) 3
1-s2.0-S1347436718300478-mmc1.docx